Document Detail

Biomarkers in Parkinson's disease.
MedLine Citation:
PMID:  16784406     Owner:  NLM     Status:  MEDLINE    
Parkinson's disease (PD) is a common neurodegenerative disorder that is largely diagnosed and managed clinically. Biomarkers, as indicators of underlying biological processes, offer the potential to identify individuals at risk for PD, screen new therapies, assist in the diagnosis and help optimize management of PD. However, to date, biomarkers, despite their considerable promise, have had limited utility in clinical trials and practice.
E Ray Dorsey; Robert G Holloway; Bernard M Ravina
Related Documents :
20967186 - Therapeutic and aesthetic uses of photodynamic therapy part five of a five-part series:...
21220386 - Allocation decisions and patient preferences in emergency medicine.
20369156 - Are general practice networks 'ready' for clinical data management?
21595336 - Mentoring for the next generation of new managers.
112606 - Some linguistic considerations related to the issue of female orgasm.
24937486 - Assessing the impact of human activities on british columbia's estuaries.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of neurotherapeutics     Volume:  6     ISSN:  1744-8360     ISO Abbreviation:  Expert Rev Neurother     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-06-20     Completed Date:  2006-07-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101129944     Medline TA:  Expert Rev Neurother     Country:  England    
Other Details:
Languages:  eng     Pagination:  823-31     Citation Subset:  IM    
University of Rochester Medical Center, 1351 Mt. Hope Avenue, Suite 223, Rochester, NY 14620, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / metabolism
Parkinson Disease / diagnosis*,  genetics,  metabolism
Reg. No./Substance:
0/Biological Markers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Olanzapine: a 5-year perspective.
Next Document:  Birth defects and epilepsy medication.